Racotumomab

Summary

Racotumomab (CHEMBL1743059) is a phase-3 clinical-stage antibody; indicated across 2 conditions including non-small cell lung carcinoma and neuroblastoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743059
Name	Racotumomab
Type	Antibody
Max phase	3

Also known as: Racotumomab, RACOTUMOMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
neuroblastoma	2	MONDO:0005072	EFO:0000621

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01460472	PHASE3	UNKNOWN	Immunotherapy With Racotumomab in Advanced Lung Cancer
NCT01240447	PHASE2	COMPLETED	Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
NCT02998983	PHASE2	COMPLETED	Racotumomab in Patients With High-risk Neuroblastoma
NCT01598454	PHASE1	COMPLETED	Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).